Serratia marcescens
Experimental TherapeuticsActivity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescensThe Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem...
SusceptibilitySynergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation AssaysSusceptibility of ceftazidime-avibactam and in vitro synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant Acinetobacter baumannii isolates harboring oxacillinases and 5 Serratia marcescens isolates carrying blaKPC-2...
- Epidemiology and SurveillanceProtracted Regional Dissemination of GIM-1-Producing Serratia marcescens in Western Germany
- Letter to the EditorSME-2-Producing Serratia marcescens Isolate from Switzerland
- Mechanisms of ResistanceSME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing β-Lactamases
- Mechanisms of ResistanceCloning, Sequencing, and Characterization of the SdeAB Multidrug Efflux Pump of Serratia marcescens